India, May 5 -- Nanobiotix S.A. (NBTX), a biotechnology company focused on nanoparticle-based cancer treatments, announced Monday positive full results from the completed dose escalation and dose expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer or PC.
The results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients with locally advanced or borderline resectable PC.
Based on the safety and preliminary efficacy findings, investigators concluded that further evaluation of JNJ-1900 (NBTXR3) is warranted in a randomized study.
Nanobiotix is in a license deal for the global co-development and commercializ...